Trump Drug-Import Tariffs ’Change Equation’ for US Production: Bhargava
PositiveFinancial Markets

Manoj Bhargava's HANS Scientific is significantly increasing its investment in U.S. pharmaceutical production, a move that could reshape the industry landscape. This shift comes in response to new drug-import tariffs introduced by the Trump administration, which are designed to encourage domestic manufacturing. By ramping up local production, Bhargava aims to enhance the availability of essential medications while potentially reducing costs for consumers. This development is crucial as it not only supports the U.S. economy but also addresses concerns about drug shortages and reliance on foreign suppliers.
— Curated by the World Pulse Now AI Editorial System